LONDON, ON, Jan. 11, 2012 /CNW/ - Notice of certification of a class
action relating to the drug Neurontin® (gabapentin) is being disseminated today. The action alleges that use
of Neurontin®, a prescription anticonvulsant that is commonly prescribed for
off-label uses, results in an increased risk of experiencing suicidal
behaviour. The action applies to all Canadians who were prescribed and
ingested the drug Neurontin® prior to August 5, 2004.
Among the issues the court approved for determination at trial are
whether Neurontin® is ineffective and/or defective or unfit for the purpose for which it
was intended and sold, and whether Pfizer breached a duty to warn class
members or materially misrepresented any of the risks of harm from
using Neurontin®. Another issue approved for determination is whether the class can
elect to require Pfizer to account for all or part of the gross revenue
or net income received from the sale of Neurontin®.
Class members are represented by the law firm Siskinds LLP in London, Ontario, and the law firms Dunn & Company and Hanson Wirsig
Matheos in Vancouver, British Columbia. Michael J. Peerless, a partner
with the law firm Siskinds LLP said that "We are very pleased that individuals across Canada who
experienced suicidal behaviour from using Neurontin®, and their family members, will be allowed to go forward with their
claims on a class basis. We look forward to taking the next steps in
this litigation and to continue pressing forward in representing the
claims of these individuals."
It is too early at this stage to quantify the claims of class members if
the action is successful, but it is anticipated that the amount will be
significant. Any Canadians who have used Neurontin® are encouraged to visit www.classaction.ca or call Joan Stewart at 1-800-461-6166 ext. 2382.
SOURCE Siskinds LLP
For further information:
Please contact Matthew Baer at (519) 660-7782 or Michael Peerless at (519) 660-7866 for English enquiries or Nathalie Boulay at (418) 694-2009 for French enquiries.